Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Charles C Bell, Katie A Fenne, Yih-Chih Chan, Florian Rambow, Miriam M Yeung, Dane Vassiliadis, Luis Lara, Paul Yeh, Luciano G Martelotto, Aljosja Rogiers, Brandon E Kremer, Olena Barbash, Helai P Mohammad, Timothy M Johanson, Marian L Burr, Arindam Dhar, Natalie Karpinich, Luyi Tian, Dean S Tyler, Laura MacPherson Show all
Nature Communications | NATURE PUBLISHING GROUP | Published : 2019
Awarded by Howard Hughes Medical Institute international research scholarship
Awarded by NHMRC
Awarded by Maddie Riewoldt's Vision
Awarded by FWO
We thank Gisela Arnau, Tim Semple, Jake Carmody and Tim Holloway for advice and assistance with genomic sequencing, Susan Jackson, Kimberly Smitheman and Jacob Rubin for experimental assistance and the members of the Dawson lab for experimental assistance, helpful comments and input into the manuscript. We thank O. Van Goethem for excellent technical assistance; PDX experiments were developed by TRACE with assistance of E. Leucci, L. Rizzotto, D. Thomas, E. Gomme and K. Crevits. The Tru-Sight26 analysis was performed by S. Vander Borght. We thank the following funders for Fellowship, Scholarship and grant support - Leukaemia Foundation Australia senior fellowship and Howard Hughes Medical Institute international research scholarship 55008729 (M.A.D.), CSL Centenary fellowship (S.-J.D.), NHMRC grant 1085015, 1106444 (M.A.D) and 1128984 (M.A.D, S.-J.D.), Snowdome Foundation (P.Y., M.A.D.), Maddie Riewoldt's Vision 064728 (Y.-C.C.), Victorian Cancer Agency (E.Y.N.L., L.M.), CRUK (M.L.B.) and FWO #G.0929.16 N (J.-C.M).